ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

AstraZeneca Sells Off Biomanufacturing Plant

by Patricia L. Short
November 24, 2008 | APPEARED IN VOLUME 86, ISSUE 47

AstraZeneca has agreed to divest AstraZeneca Biotech Laboratory, a pilot plant in Södertälje, Sweden, for recombinant proteins and monoclonal antibodies, to Recipharm, a contract development and manufacturing organization. AstraZeneca will hold "a significant minority stake" in the new Recipharm subsidiary, which will supply material for Phase I and II tests of an AstraZeneca drug. AstraZeneca is consolidating all its biotech activities within MedImmune, which it acquired last year.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment